medigraphic.com
ISSN 2594-3006 (Electronic)
ISSN 2007-1752 (Print)
Archivos de Medicina de Urgencia de México

2011, Number 2

<< Back

Arch Med Urg Mex 2011; 3 (2)

Rosiglitazone. Chronicle of an announced withdrawal

Cabrera RA, Sauza SJC

Language: Spanish
References: 4
Page: 85-86
PDF size: 41.61 Kb.


Text Extraction

No abstract


REFERENCES

  1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.

  2. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-8.

  3. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009; 373 (9681): 2125-35.

  4. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the US food and drug administration. N Engl J Med 2010; 363: 16.




2020     |     www.medigraphic.com